Yutaka Kuwatsuka

Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)

Yasuhiro Nakamura, Kenjiro Namikawa, Shusuke Yoshikawa et al. · ESMO Open · 2021 · 57 citations · Full text

Medicine, Immunology, Oncology +17

Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients

Yasuhiro Nakamura, Kenjiro Namikawa, Yukiko Kiniwa et al. · European Journal of Cancer · 2022 · 44 citations

Medicine, Immunology, Oncology +17

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study

Yoshiyasu Umeda, Shusuke Yoshikawa, Yukiko Kiniwa et al. · European Journal of Cancer · 2021 · 41 citations

Medicine, Immunology, Oncology +16

Increased serum levels of soluble CD163 in patients with scleroderma

Kazuhiro Shimizu, Fumihide Ogawa, Ayumi Yoshizaki et al. · Clinical Rheumatology · 2012 · 32 citations · Full text

Medicine, Clinical Sciences, Immunology +9

Yusho patients show increased serum IL-17, IL-23, IL-1β, and TNFα levels more than 40 years after accidental polychlorinated biphenyl poisoning

Yutaka Kuwatsuka, Kazuhiro Shimizu, Yuichiro Akiyama et al. · Journal of Immunotoxicology · 2013 · 28 citations · Full text

Pharmacy, Immunology, Toxicology +15